

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel in the order listed on Form Page 2.  
Follow this format for each person. DO NOT EXCEED FOUR PAGES.

NAME ANIL POTTI		POSITION TITLE FELLOW, DIVISION OF HEMATOLOGY/ONCOLOGY	
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Christian Medical College, Vellore, India	M.B;B.S	1989 - 1995	Medicine
University of North Dakota School of Medicine, ND	Residency	1996 - 1999	Internal Medicine
Duke University Medical Center, Durham, NC	Fellowship	2003 - 2006	Hematology/Oncology

**HONORS and AWARDS:**

- 1996 Rhodes Scholar (Australian Board).  
 1997 Intern of the Year (UND Residency Training Program).  
 1997 Resident Teacher of the Year – UND School of Medicine.  
 1998 American Society of Clinical Oncology (ASCO) Merit Award.  
 1998 Young Investigator Award - American Federation for Medical Research and Central Society for Clinical Research (AFMR/CSCR).  
 1998 Research Competition Winner at the Annual American College of Physicians (ACP) Scientific Meeting.  
 1999 Alpha-Omega-Alpha (AOA) Honor Society Membership.  
 1999 American Society of Hematology (ASH) Trainee Award.  
 1999 Assistant Professor of Medicine, UND School of Medicine and Health Sciences, Fargo, ND.  
 2000. UND Academic & Teaching Excellence Award.  
 2001 Cure for Lymphoma & Lymphoma Research Foundation Junior Faculty Award.  
 2001 Young Investigator Award - Central Society of Clinical Research (CSCR)  
 2002 Golden Apple Award (teaching award from medical students).  
 2002 Distinguished Faculty Award (teaching award from residents).  
 2002 Associate Professor of Medicine, UND School of Medicine and Health Sciences, Fargo, ND.  
 2003 Arnold P. Gold Foundation - Humanism in Medicine Award.  
 2003 Golden Apple Award (teaching award from medical students).  
 2003 Frank N. Low Research Prize.

**PUBLICATIONS: (selected of a total of 67 publications)**

- 1) **Potti A**, Forseen S, Koka VK, Koch M. Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am J Clin Oncol. 2003;26(4):332-5.
- 2) Ganti AK, Mehdi SA, **Potti A**. Chromosomal anomalies in coexistent myeloproliferative disorders. Cancer Genet Cytogenet. 2003;145(2):172-5.
- 3) Sanford M, Moazzam N, Lang M, Hanley JF, **Potti A**. Anticoagulation patterns and clinical decision-making following an intermediate ventilation-perfusion scan in pulmonary thromboembolism. J Thromb Haemost. 2003;1(6):1321-3.
- 4) Ganti AK, **Potti A**, Koka VK, Pervez H, Mehdi SA. Myeloproliferative syndromes and the associated risk of coronary artery disease. Thromb Res. 2003 May 1;110(2-3):83-6.

- 5) **Potti A**, Panwalkar AW, Langness E. Prevalence of pesticide exposure in young males ( $\leq$  50 years) with adenocarcinoma of the prostate. *J Carcinog*. 2003;15;2(1):4.
- 6) **Potti A**, Panwalkar A, Sholes K, Lewis MJ, Hanley JF. Ineffectiveness of measuring routine vital signs in adult inpatients with deep venous thrombosis. *Clin Appl Thromb Hemost*. 2003;9(2):163-6.
- 7) **Potti A**, Panwalkar A, Ingebretson MC, Tharapel SA, Goodell M, Dayton MV, Mehdi SA. An indolent B-cell lymphoma with t(2;8)(p12;q24) abnormality and absence of C-MYC amplification and TP53 deletion. A new variant? *Cancer Genet Cytogenet*. 2003;144(1):76-9.
- 8) Howe C, Paschal C, **Potti A**. A model for clinical estimation of perioperative hemorrhage. *Clin Appl Thromb Hemost*. 2003;9(2):131-5.
- 9) **Potti A**, Moazzam N, Ramar K, Hanekom DS, Kargas S, Koch M. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. *Ann Oncol*. 2003;14(6):894-7.
- 10) Foster H, Knox S, Ganti AK, Hebert BJ, Koch M, Tendulkar K, Levitt R, **Potti A**. HER-2/neu overexpression detected by immunohistochemistry in soft tissue sarcomas. *J Clin Oncol*. 2003;26(2):188-91.
- 11) **Potti A**, Ganti AK, Koch M, Levitt R, Mehdi SA. Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma. *Leuk Lymphoma*. 2002;43(12):2427-30.
- 12) Abdel-Raheem M, **Potti A**, Tadros S, Koka VK, Hanekom D, Fraiman D, Danielson BD. Effect of low-molecular-weight heparin on potassium homeostasis. *Pathophysiol Haemost Thromb*. 2002;32(3):107-10.
- 13) Malik A, **Potti A**, Ganti AK, Hanley JF. Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. *Am J Gastroenterol*. 2002;97(6):1371-4.
- 14) Ganti AK, Yeganarayan R, **Potti A**. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 levels in acute myocardial infarction. *Pathophysiol Haemost Thromb*. 2002;32(2):80-4.
- 15) Ramar K, Hauer D, **Potti A**, Lo T. Ecthyma gangrenosum in chronic lymphocytic leukaemia. *Lancet Infect Dis*. 2003;3(2):2325-27.
- 16) Abdel-Raheem M, **Potti A**, Hebert B, Danielson BD. Hyperhomocysteinemia and the risk of thromboembolic phenomenon in patients with chronic renal failure. *Thromb Res*. 2002;15;105(4):299-302.
- 17) **Potti A**, Willardson J, Forseen C, Kishor Ganti A, Koch M, Hebert B, Levitt R, Mehdi SA. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. *Lung Cancer*. 2002;36(3):257-61
- 18) **Potti A**, Malik AA, Ganti AK, Koch M, Leitch J. Immunoglobulin and T-cell receptor gene-gene rearrangement in pleural cavity-based T-cell rich B-cell lymphoma in an immunocompetent patient. *Leuk Lymphoma*. 2002;43(1):195-8.
- 19) Abdel-Raheem M, **Potti A**. Severe Evans's syndrome secondary to interleukin-2 therapy: treatment with chimeric monoclonal anti-CD20 antibody. *Ann Hematol*. 2001;80(9):543-5.
- 20) Gill N, Malik A, **Potti A**, Saberi A, Mehdi SA. Role of HER-2/neu overexpression in colorectal carcinoma. *Gastroenterology*. 122(1):248-250, 2002.
- 21) Schell DA, Ganti A, Levitt R, **Potti A**. Thrombocytopenia associated with c7E3 Fab therapy in acute coronary syndromes. *Annals of Hematology*. 90:46-51, 2002.
- 22) Abdel Raheem MM, **Potti A**, Saberi A, Becker W, Mehdi SA. Late adrenal metastases in operable non-small cell lung carcinoma – A review. *American Journal of Clinical Oncology*. 24(6) 441-446, 2002.
- 23) **Potti A**, Abdel-Raheem MM, Schell DA, Levitt R, Mehdi SA. Intramedullary spinal cord metastases from non-small cell carcinoma of the lung – clinical patterns, diagnosis and management. *Lung Cancer*. 31(2):319-323, 2001.
- 24) **Potti A**, Schell DA. Acute adrenal insufficiency in lung cancer. *Journal of Clinical Oncology*. 19(17):3780-3782, 2001.
- 25) **Potti A**, Langness E, Ganti A, Koch M, Mehdi SA, Levitt R. Determination of HER-2/neu overexpression and the incidence of lung carcinoma among non-smokers with chronic lymphocytic leukemia. *Lung Cancer*. 34:227-232, 2001.
- 26) Pandita D, Steen P, **Potti A**. Risk factors for deep venous thrombosis of the upper extremities. *Annals of Internal Medicine*. 127(12):1129, 1997.

**RESEARCH EXPERIENCE:**

1995 – 1996            Research Fellowship at Queensland Research Institute, Australia, to study the cardiac effects of beta-thalassemia/HgbE disease in south-east Asians.

**RESEARCH GRANTS (over the past 3 years):**

1. Principal Investigator/Research Awardee of grant # DMF0016289 from Dakota Medical Foundation to evaluate HER-2/neu as a prognostic marker in solid tumors.
2. Principal Investigator/Research Awardee of grant # IMF200035 to evaluate HER-2/neu as a prognostic marker in B-cell lymphoproliferative disorders.
3. Principal Investigator of grant from Aplastic anemia and MDS International Society to determine the role of exposure to pesticides on the incidence of myelodysplastic syndromes/aplastic anemia.
4. Principal Investigator/New Investigator Award for a proposed grant from the Congressionally Directed Medical Research Program (CDMRP) to evaluate the relationship of exposure to pesticides on the incidence/prevalence of prostate carcinoma and the effect of 'exposure' on the prevalence of clinicobiologic variables (HER-2/neu overexpression and estrogen/progesterone receptor status).
5. Efficacy of routine measurement of vital signs in hospitalized patients with thrombotic diseases – Principal investigator/Grant awardee from Meritcare Medical Foundation (grant #119275)
6. Principal Investigator – Grant awardee from DMF to study the role of c-kit (CD117) overexpression in conjunction to HER-2/neu overexpression in patients with primary malignant lung and brain tumors.
7. Principal Investigator of an unrestricted research grant from IMPATH laboratories, CA, to study the role of c-kit (CD117) overexpression in patients with extensive stage small cell lung cancer.